Literature DB >> 1496198

Sample sizes for proportional hazards survival studies with arbitrary patient entry and loss to follow-up distributions.

N A Yateman1, A M Skene.   

Abstract

In proportional hazards survival studies, power depends on the observed number of deaths, d*. For a given choice of survival, loss, and patient entry distributions, sample sizes can be determined by equating d* to the expected number of deaths. Approximating the survival and loss distributions with piecewise exponential distributions, and patient entry with a piecewise linear distribution, significantly reduces the computational overhead, and the expected number of deaths can be evaluated routinely. The merits of this approach are illustrated by a clinical trial of chemotherapy for large bowel cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1496198     DOI: 10.1002/sim.4780110812

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Sample size calculation for rank tests comparing K survival distributions.

Authors:  Sin-Ho Jung; Siu Hui
Journal:  Lifetime Data Anal       Date:  2002-12       Impact factor: 1.588

2.  Optimal two-stage log-rank test for randomized phase II clinical trials.

Authors:  Minjung Kwak; Sin-Ho Jung
Journal:  J Biopharm Stat       Date:  2016-04-06       Impact factor: 1.051

3.  On sample size calculation for comparing survival curves under general hypothesis testing.

Authors:  Sin-Ho Jung; Shein-Chung Chow
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

4.  Phase II cancer clinical trials for biomarker-guided treatments.

Authors:  Sin-Ho Jung
Journal:  J Biopharm Stat       Date:  2017-11-27       Impact factor: 1.051

5.  Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks.

Authors:  Qing Yang; Wing K Fung; Gang Li
Journal:  Stat Med       Date:  2017-12-27       Impact factor: 2.497

Review 6.  Design and Analysis of Cancer Clinical Trials for Personalized Medicine.

Authors:  Sin-Ho Jung
Journal:  J Pers Med       Date:  2021-05-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.